Zürich, Zurich, Switzerland Swiss Life Private Equity Partners appeared to be the Corporate Investor, which was created in 1857. The leading representative office of defined Corporate Investor is situated in the Zu00fcrich. The company was established in Europe in Switzerland.
The higher amount of exits for fund were in 2005. The important activity for fund was in 2001. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Swiss Life Private Equity Partners performs on 71 percentage points more the average number of lead investments.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Swiss Life Private Equity Partners, startups are often financed by Techno Venture Management, Oxford Bioscience Partners, Advent International. The meaningful sponsors for the fund in investment in the same round are Techno Venture Management, Yasuda Enterprise Development, Wheatley MedTech Partners. In the next rounds fund is usually obtained by Western Technology Investment, Thuja Capital, Techno Venture Management.
Among the most popular fund investment industries, there are Health Care, Manufacturing. Among the most popular portfolio startups of the fund, we may highlight Zeptosens, Phenex Pharmaceuticals, Enanta Pharmaceuticals. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Phenex Pharmaceuticals | $7M | 21 Sep 2010 | Baden-Württemberg | ||
iolon, inc. | $7M | 25 Apr 2002 | San Jose, California, United States | ||
| $15M | 27 Feb 2001 | Bern, Switzerland | |||
Acorda Therapeutics | $33M | 08 Jan 2001 | New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Phenex Pharmaceuticals | $7M | 21 Sep 2010 | Baden-Württemberg | ||
iolon, inc. | $7M | 25 Apr 2002 | San Jose, California, United States | ||
| $15M | 27 Feb 2001 | Bern, Switzerland | |||
Acorda Therapeutics | $33M | 08 Jan 2001 | New York, United States |
